DXCM Share Price Performance
US$70.02
-19.05 (-21.39%)
17.8% undervalued intrinsic discount
US$85.19
Fair Value
Price US$70.02
AnalystConsensusTarget US$85.19
Fair ValueUS$85.19
Share Pricen/a
DexCom, Inc. Stock Price
- 1 Narratives written by author
- 1 Comments on narratives written by author
- 135 Fair Values set on narratives written by author
DXCM Community Narratives
AN
Fair Value US$85.19 17.8% undervalued intrinsic discount
DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty
0users have liked this narrative
1users have commented on this narrative
68users have followed this narrative
DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty
Key Takeaways Expanded reimbursement and international coverage unlock new patient segments, fueling sustained revenue growth while diversifying global revenue streams. Advances in product innovation, digital integration, and operational efficiencies drive higher margins, recurring revenues, and increased patient loyalty.Read more
767
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
68users have followed this narrative
AN
US$85.19
17.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
12.66% p.a.
Profit Margin
22.05%
Future PE
29.04x
Price in 2029
US$106.62
Trending Discussion
Recently Updated Narratives
AN
DXCM: Medicare Support And AI Coaching Features Will Sustain Long-Term Confidence
Fair Value: US$85.19 17.8% undervalued intrinsic discount
68 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
DexCom, Inc. Key Details
About DXCM
- Founded
- 1999
- Employees
- 10250
- CEO
- WebsiteView website
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
